Gammadelta T cells for immune therapy of patients with lymphoid malignancies. - Wikidata - awgldk - TriplyDB

Gammadelta T cells for immune therapy of patients with lymphoid malignancies.

Gammadelta T cells for immune therapy of patients with lymphoid malignancies.

http://www.wikidata.org/entity/Q44353687

about

Successful adoptive transfer and in vivo expansion of haploidentical γδ T cells Recent advances in haploidentical hematopoietic stem cell transplantation using ex vivo T cell-depleted graft in children and adolescents Targeted Therapies in Adult B-Cell Malignancies What lessons can be learned from γδ T cell-based cancer immunotherapy trials?γδ T Cell Immunotherapy-A Review Role of natural killer and Gamma-delta T cells in West Nile virus infection γδ T cells for cancer immunotherapy: A systematic review of clinical trials Harnessing the power of Vδ2 cells in cancer immunotherapy The role of gamma delta T cells in haematopoietic stem cell transplantation Haploidentical Hematopoietic Stem Cell Transplantation as a Platform for Post-Transplantation Cellular Therapy Self/non-self discrimination by human gammadelta T cells: simple solutions for a complex issue?Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer A Subset of Protective γ9δ2 T Cells Is Activated by Novel Mycobacterial Glycolipid Components A rapid crosstalk of human gammadelta T cells and monocytes drives the acute inflammation in bacterial infections Highly active microbial phosphoantigen induces rapid yet sustained MEK/Erk- and PI-3K/Akt-mediated signal transduction in anti-tumor human gammadelta T-cells.Human cytomegalovirus elicits fetal gammadelta T cell responses in utero Adoptively transferred ex vivo expanded gammadelta-T cells mediate in vivo antitumor activity in preclinical mouse models of breast cancer.Anti-Tumor Activity and Immunotherapeutic Potential of a Bisphosphonate Prodrug.{gamma}{delta} T cell homeostasis is established in competition with {alpha}{beta} T cells and NK cells.Sensitization of ovarian carcinoma cells with zoledronate restores the cytotoxic capacity of Vγ9Vδ2 T cells impaired by the prostaglandin E2 immunosuppressive factor: implications for immunotherapy.Individual Vgamma2-Jgamma1.2+ T cells respond to both isopentenyl pyrophosphate and Daudi cell stimulation: generating tumor effectors with low molecular weight phosphoantigens.Vγ9Vδ2 T lymphocytes activation in osteoporotic patients treated with bisphosphonates.Large-scale expansion of γδ T cells and peptide-specific cytotoxic T cells using zoledronate for adoptive immunotherapy.Lysis of aminobisphosphonate-sensitized MCF-7 breast tumor cells by Vγ9Vδ2 T cells.γδ T cells cross-link innate and adaptive immunity in Mycobacterium tuberculosis infection.Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies Immune therapy for breast cancer in 2010-hype or hope?Metabolic engineering of Salmonella vaccine bacteria to boost human Vγ2Vδ2 T cell immunity.Targeting γδ T cells for immunotherapy of HIV disease Preferential Th1 cytokine profile of phosphoantigen-stimulated human Vγ9Vδ2 T cells.γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody.Plasticity of γδ T Cells: Impact on the Anti-Tumor Response Clinical applications of gamma delta T cells with multivalent immunity.Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy.The Vγ9Vδ2 T Cell Antigen Receptor and Butyrophilin-3 A1: Models of Interaction, the Possibility of Co-Evolution, and the Case of Dendritic Epidermal T Cells.A quantitative deficiency in peripheral blood Vγ9Vδ2 cells is a negative prognostic biomarker in ovarian cancer patients.Vgamma2Vdelta2 T Cell Receptor recognition of prenyl pyrophosphates is dependent on all CDRs Rapamycin increases the yield and effector function of human γδ T cells stimulated in vitro.Effector Vγ9Vδ2 T cells dominate the human fetal γδ T-cell repertoire Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours.

P2860

Q21245481-EFF575C4-51E7-443D-BA38-FD2BB590B215 Q26750995-2606F53C-14A1-467F-BEC0-D7BB5263B069 Q26783195-97E9CCBC-467B-47F1-BB61-ED029AF4793E Q26849323-009C2FF6-0BB8-4896-87E8-FB880329C78A Q26995102-A81828E6-4C73-49DF-BC04-7C6F10115312 Q27007830-1CDDFF02-7F6C-4B57-B652-68753CEB75F1 Q27021705-112B9FDC-9B6C-4EBF-8275-DA2DA6CC533D Q27027547-A77213AA-3645-4413-AFDD-DB2B1BD23575 Q27030355-6ED81EBC-4063-4D7A-A217-C13F0EBC73F7 Q28085397-4089C149-DA8F-4C9A-A118-8F44B7DB475A Q28287583-4C9D4770-CB01-4EDE-A757-9AFFD4BB5460 Q28659468-45AEDAC1-80E2-46A4-B1C3-03A142EC58B1 Q28829233-D9F7454C-A04C-4BF9-9961-4C1974BA3AE0 Q33410795-FEBB7539-D2EE-4EEE-83B7-91F94CBC36BA Q33455830-3981D65B-7819-4382-A88A-777707E0F999 Q33795023-10AFBB4B-8FA3-4DAD-AA7B-61BA07E515E1 Q33905819-54CE663C-64B8-4F5C-91F7-812203481A18 Q33920919-963AEA9B-39F9-4695-ADED-836612E74947 Q34055649-33A1FEEA-D144-491B-B891-C3D641EAF0F0 Q34077388-73F1DE80-8AC6-41FD-81A4-6FD919A40874 Q34170227-D5D39F91-613F-46EA-AF2E-5DA04301EAEA Q34230320-8928A69B-E3DF-40D0-8AD6-4A0A5BDDBCE6 Q34372167-0D345914-9C1B-4B17-AECA-ABB3277CCFA1 Q34395222-AD90445C-66CE-46C2-92E3-5642A6A1C58F Q34496948-3618D962-A34D-495C-9D6E-FF7C7798C1AF Q34517192-67C1F500-AC6B-4267-B065-1CAAE1A98F4F Q34541467-8B3B79E4-F176-43CE-8585-E416098BF002 Q34560345-CC86F3CB-929F-4C4B-B982-7992A31A7DD8 Q34585223-6DF5DF01-A23C-44D6-BC4B-640455DC865B Q34595188-E568EA21-5572-4970-9FC2-F2F8D388D907 Q34612619-A99AA182-3E64-44C5-A9F2-AE5370D81636 Q34652408-FC7E48B4-0864-480E-9DA2-F6325BDE41CF Q34677859-1334D612-996B-4428-A1DC-06168C39F738 Q34681370-D21BBD4C-E426-471F-A921-1A5AFBDB3F84 Q34741552-0A6BF6A1-655A-44E0-ACB6-DF330FBF01A3 Q34743969-72AE8353-9651-4A4C-B561-0827B3AEABAA Q34749889-D34B4951-3DCD-498E-AED8-AD8476FE214F Q34802235-0FA023B9-2F7D-49AE-8F58-B0E53E52B16E Q35090079-C918E012-6637-4787-82E3-91765206F8BA Q35208161-AF3B42AE-D2D9-43AA-B337-4C6CB874D701

P2860

Gammadelta T cells for immune therapy of patients with lymphoid malignancies.

http://www.wikidata.org/entity/Q44353687

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh-hant

name

Gammadelta T cells for immune therapy of patients with lymphoid malignancies.

@en

Gammadelta T cells for immune therapy of patients with lymphoid malignancies.

@nl

type

label

Gammadelta T cells for immune therapy of patients with lymphoid malignancies.

@en

Gammadelta T cells for immune therapy of patients with lymphoid malignancies.

@nl

prefLabel

Gammadelta T cells for immune therapy of patients with lymphoid malignancies.

@en

Gammadelta T cells for immune therapy of patients with lymphoid malignancies.

@nl

P1433

Q44353687-5AC5CEB8-618A-4FEF-80EA-453CF07D52A4

P1476

Q44353687-416D964A-E19D-4313-92C6-A3506C33BA40

P2093

Q44353687-2A795257-E097-4C78-9957-19ED0A093BDE

Q44353687-75547D34-330B-47B2-B447-8A25DD47BF03

Q44353687-7B7D19C9-60D6-4304-8B50-14489BFAECDD

Q44353687-85568E53-F7E7-4356-AFA5-D46C38836AE3

Q44353687-9A2F0115-F1FC-428B-B131-98B58449C70B

Q44353687-B5C2E427-AF29-46EC-8EB6-3C43519AD47A

P304

Q44353687-B6EA8A61-22D3-4E40-AAF2-74EDB2BB8511

P31

Q44353687-C14957BB-47B2-4F34-86E9-6B0353737D9A

P356

Q44353687-6CEBDFB5-F124-4B5E-87CB-6D07F75303CA

P407

Q44353687-BBFDA865-CB98-4F55-AA3C-F61B93981C1E

P433

Q44353687-ACE4F9F2-E0FB-4299-9483-074D67C03565

P478

Q44353687-598AC0FA-2F5B-48B6-B5E8-B42A1AEF528A

P50

Q44353687-F66AB234-DB35-4C40-AA14-34BF5847EF8B

P577

Q44353687-EAA69F3B-F338-4626-8685-6B67E60BFC74

P5875

Q44353687-0038F032-5FA5-4C39-AA8C-2760E19854EA

P698

Q44353687-70447949-E082-4538-AE2F-F2049A11D45F

P921

Q44353687-02E1C257-0729-4B5E-8B1E-F61911939D5E

P356

BLOOD-2002-12-3665

P1433

P1476

Gammadelta T cells for immune therapy of patients with lymphoid malignancies.

@en

P2093

Florian Weissinger

http://www.w3.org/2001/XMLSchema#string

Martin Wilhelm

http://www.w3.org/2001/XMLSchema#string

Peter Reimer

http://www.w3.org/2001/XMLSchema#string

Susanne Eckstein

http://www.w3.org/2001/XMLSchema#string

Thomas Ruediger

http://www.w3.org/2001/XMLSchema#string

Volker Kunzmann

http://www.w3.org/2001/XMLSchema#string

P304

200-206

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2002-12-3665

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

102

http://www.w3.org/2001/XMLSchema#string

P50

Hans-Peter Tony

P577

2003-03-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10867482

http://www.w3.org/2001/XMLSchema#string

P698

12623838

http://www.w3.org/2001/XMLSchema#string

P921